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Presence of Chlamydia trachomatis in endocervix was determined in 2466 women attending a tertiary care hospital in New
Delhi, India over a period of 16 years, using a monoclonal-based direct immunoﬂuorescence assay, tissue culture isolation, and a
conventional PCR assay. Chlamydia antigen could be detected in 391 out of 2466 (15.85%) of patients studied; in 27.27% women
with PID, 16.74% women with cervicitis, 16.03% women with infertility, and 12.06% women with adverse pregnancy outcomes,
respectively. There was a statistically signiﬁcant decreasing trend in Chlamydia antigen positivity between the years 1994–1999 and
2000–2004; the apparent decline in antigen positivity between the years 2000–2004 and 2005–2010 was not statistically signiﬁcant.
AntigendetectionassaydetectedequalnumberofpositivesasthePCRassay;tissuecultureisolationdemonstratedlowerpositivity.
In a few representative specimens from cervicitis patients, genotyping was done using RFLP pattern analysis of C. trachomatis
MOMP gene ampliﬁed by PCR assay, all of these belonged to Chlamydia trachomatis serovar E.
1.Introduction
Chlamydia trachomatis was recognized as an important
sexually transmitted pathogen after 1970 [1]. Genital C. tra-
chomatis infections have emerged as the most prevalent sex-
ually transmitted diseases of bacterial origin [2]. In women,
the infection usually manifests as urethritis, cervicitis, salp-
ingitis, and endometritis though a large proportion of the
women remain asymptomatic. If untreated, complications
and sequelae such as pelvic inﬂammatory disease (PID),
ectopic pregnancy and tubal infertility, and still birth with
important socioeconomic consequences are common [3].
To initiate early and appropriate therapy, deﬁnitive
laboratory diagnosis should be available to the physicians
as soon as possible. The physicians should also be aware
of the prevalence of infection in their patients to arrive at
a quick presumptive diagnosis, since most of the patients
remain asymptomatic. Previous studies from diﬀerent parts
of the world, documented that 12–33% of women attending
STD clinics and the gynecologist’s clinics with cervicitis
harbored Chlamydia in their cervices [4–6]. In India the
prevalence reported from a small study was 10.5% in women
in the age group of 20–30 years in Southern India in
2009 [7]. An earlier single point study in 1993 from New
Delhi, India reported that 41% of women with vaginal
discharge(cervicitis)and36%ofwomenwithinfertilitywere
C. trachomatis positive [8] .H o w e v e rn ol o n g - t e r ms t u d y
spanning several years regarding C. trachomatis involve-
ment in female genital infections has been reported from
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C. trachomatis consists of 18 serovars, A-K, L1-L3,D a,
Ia,a n dL 2a; serovars D-K and L1-L3 are implicated in
genital infections. Determination of causative C. trachomatis
serovar by conventional methods is cumbersome and usually
diﬃcult as the serovar-speciﬁc antibodies are not com-
mercially available. The polymerase chain reaction (PCR)
assay along with restriction fragment length polymorphism
(RFLP) analysis of the major outer membrane protein
(MOMP) coding gene was successfully used for genotyping
of C. trachomatis from clinical specimens [9, 10]. Scanty
information is available regarding the prevalent serovars
or genotypes of C. trachomatis causing infections from
India.
Weareregularlytestingforthepresenceof C.trachomatis
infection in women of child-bearing age coming to the
gyneaecology clinic of our hospital for the last 16 years.
Furthermore, we genotyped few of the C. trachomatis
from cervical specimens using RFLP pattern analysis of the
major outer membrane protein (MOMP) coding gene of C.
trachomatis ampliﬁed by PCR assay.
2.MaterialsandMethods
2.1. Study Population. From 1994 to 2010, a total of 2466
women in the age group of 20–50 years clinically suspected
of having C. trachomatis-related infections and attending
the Obstetrics and Gynecology Clinic of All India Institute
of Medical Sciences, New Delhi, were included in this
study. These comprised of 436 cases of cervicitis, 1671
cases of infertility, 44 cases of pelvic inﬂammatory disease
(PID), and 315 cases with adverse pregnancy outcomes
(BOH).
2.2. Specimen Collection. After informed consent, endocer-
vical swabs were collected using a sterile cotton wool swab
from the endocervical canal by rotating the swab vigorously
for 16–30 seconds. Three separate swabs were collected
randomly; one was smeared onto the well of a Teﬂon-coated
glass slide for direct ﬂuorescent antibody (DFA) test, and
the other two were placed in vials containing 0.2M sucrose
phosphate buﬀer (0.2MSP) medium and transported to the
laboratory on ice immediately for PCR assay and tissue
culture isolation.
2.3. Direct Immunoﬂuorescence Assay (DFA) for Antigen De-
tection. All the 2466 specimens were processed for Chlamy-
dia antigen detection. Chlamydia trachomatis direct speci-
men kit (MicroTrak, USA) was used for the purpose accord-
ing to the manufacturer’s instructions as described before
[11, 12]. Brieﬂy, the smears were ﬁxed with cold methanol
and stained with ﬂuorescent tagged anti-Chlamydia mon-
oclonal antibody (Syva Microtrack, USA) for 30 minutes
at 37◦C in a humid chamber. The slides were washed
with phosphate buﬀer saline for 10 minutes followed by
double distilled water for 5 minutes, air-dried, mounted, and
observed under the ﬂuorescent microscope (Nikon, Japan).
The positive and negative control sides provided by the
manufacturers (Syva Microtrack, USA) were included in
each batch of the test.
2.4. Isolation of C. trachomatis in Tissue Culture. Tissue
culture isolation of C. trachomatis was done from 1507
of the specimens. The endocervical swabs collected in
0.2MSP buﬀer were inoculated onto Mitomycin-C-treated
conﬂuent monolayers of McCoy cells grown on cover slips
in shell vials via centrifugation at 2000rpm, according
to the method described previously [13]. The inoculated
monolayers were incubated at 35◦C for 72 hours. The
cover slips were taken out, washed with PBS and stained
with FITC tagged anti-Chalmydia monoclonal antibodies
according to manufacturer’s instructions using Chlamydia
trachomatis culture conﬁrmation test kit (MicroTrak, USA).
The cover slips were mounted and observed under the
ﬂuorescent microscope (Nikon, Japan) for C. trachomatis
inclusions in Mc Coy cells. Appropriate positive control
{C. trachomatis L2 (434 Bu strain)} and negative control
(0.2MSP buﬀer) were included in each batch of the test.
2.5. Diagnostic PCR Assay for Ampliﬁcation of 517bp Region
of C. trachomatis Cryptic Plasmid. An in-house conventional
PCR assay for ampliﬁcation of a 517bp region of C. tra-
chomatis cryptic plasmid was used in 333 endocervical spec-
imens from patients with cervicitis using a set of published
primers [14], as per the method used by us previously
[12]. DNA extracted from C. trachomatis L2 (434 Bu strain)
grown in the yolk sac of embryonated hen’s egg and puriﬁed
by renograﬃn gradient centrifugation was used as positive
control and distilled water was used as negative control.
Adequateprecautionsweretakenforavoidingcontamination
suchasuseofseparatelaboratoryroomsforDNAextraction,
PCR assay procedure and handling of PCR products and
use of proper micropipettes. As described previously [12],
results were conﬁrmed by southern hybridization with a
radio-labeled internal probe.
2.6.RestrictionFragmentLengthPatternAnalysisoftheAmpli-
ﬁed MOMP Gene for Genotyping. For genotyping using
RFLP pattern analysis, the entire omp1 gene coding for
major outer membrane protein (MOMP) was ampliﬁed by
conventional PCR assay using a set of published primers
and procedures described by Sayada et al. [15]f r o m5 0
endocervical specimens from patients of cervicitis. A few
conjunctival specimens from clinically proven trachoma
cases were included for comparison purposes.
Brieﬂy, DNA was isolated from 500μL of thoroughly
mixed clinical specimens using proteinase K and phenol
chloroform extraction as was described before [12]. DNA
extractedfromC.trachomatisL2 (434Bustrain)growninthe
yolksacofembryonatedhen’seggandpuriﬁedbyrenograﬃn
gradient centrifugation was used as positive control and
distilled water was used as negative control.
PCR assay for ampliﬁcation of ∼1kb MOMP gene was
done in 100μLv o l u m ea sw a sd e s c r i b e dp r e v i o u s l y[ 12].
Ten μL of the PCR ampliﬁed product was electrophoresed
through a 1% agarose gel to conﬁrm the correct ampliﬁca-
tion product. The precipitated and puriﬁed DNA from the
remaining 90μL of PCR product was used for RFLP analysis
with restriction enzyme Alu I (NEB, UK), was prepared in
a2 0μL reaction mixture containing 3μg of puriﬁed DNA,Infectious Diseases in Obstetrics and Gynecology 3
Table 1: Antigen positivity in patients of various disease groups from 1994 to 2010.
Block-years Cervicitis (Pos./specimens) Infertility (Pos./specimens) PID (Pos./specimens)
BOH with adverse pregnancy
outcomes
(Pos./specimens)
I-94–99 (684) 21/104 (20.2%) 103/414 (24.9%) 8/23 (34.7%) 24/143 (16.8%)
II-2000–2004 (1011) 36/211 (17.0%) 84/631 (13.3%) 4/20 (20%) 12/149 (8%)
III-2005–2010 (690) 16/121 (13.22%) 81/626 (12.9%) 0/1 (0%) 2/23 (8.7%)
2385 58/355 268/1671 12/44 38/315
Iv e r s u sI I ;P = 0.497
I versus III P = 0.159
II versus III P = 0.354
Iv e r s u sI I ;P = 0.0001
Iv e r s u sI I IP = 0.0001
II versus III P = 0.910
I versus II; P = 0.461
I versus III P = 0.717
II versus III P = 0.419
Iv e r s u sI I ;P = 0.036
I versus III P = 0.495
II versus III P = 0.760
χ2 trend = 1.964 χ2 trend = 22.97 χ2 trend = 1.516 χ2 trend = 4.422
P = 0.161 P = 0.0001 P = 0.218 P = 0.035
15U of Alu Ie n z y m e ,a n d2μL of 10x buﬀer provided with
theenzymeandmiliQwaterqs,andwasincubatedovernight
at 37◦C. After inactivation of the enzyme at 65◦Cf o r1 0
minutes, the product was electrophoresed through a 3%
agarosegelinanelectrophoresisapparatus(LKB,Pharmacia,
Sweden), stained with ethidium bromide and visualized
under an UV transilluminator. (UVP, UK). In order to
attribute clear-cut speciﬁcity to the RFLP pattern analysis
we included a few conjunctival specimens from which the
MOMP gene was PCR-ampliﬁed, restriction-digested and
the product of this assay was electrophoresed in the same gel.
2.7. Data Analysis. STATA 11.0 was utilized for data analysis.
Data were systematically recorded and managed on an
excel spread sheet. For comparing the proportion positivity
amongst the various disease groups such as cervicitis, infer-
tility, PID and BOH, during diﬀerent time periods, a Pearson
χ2 test was used. Also χ2 test for trend was employed to
determine the signiﬁcant trend during the period. To assess
the relationship of DFA with tissue culture, we compared
the sensitivity, speciﬁcity, positive predictive value (PPV),
negative predictive value (NPV), and agreement and their
90% conﬁdence interval values.
3. Results
In the direct immunoﬂuorescence assay (DFA), the Chlamy-
dia trachomatis elementary bodies were visible as regular
bright apple green spherical particles. Any smear showing
more than 10 such particles were considered positive [12].
Table 1 and Figure 1 depict the results of the DFA tests in
the four groups of patients (total 2466) in diﬀerent block
years (1994–99, 2000–2004, and 2005–2010). A total of 391
out of 2466 (15.85%) specimens were positive for Chlamydia
antigen in DFA test. Amongst the diﬀerent categories, 73 of
436 (16.74%) women with cervicitis, 268 of 1671 (16.03%)
women with infertility, 12 (27.27%) of the 44 women with
PID, and 38 of 315 (12.06%) women with adverse pregnancy
outcomes (BOH) were antigen positive by DFA test.
As is evident grossly from Figure 1 and Table 1, there
seems to be a trend towards a gradual decline in the antigen
positivity rates over the years in all the four disease groups.
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Figure 1: Yearwise positivity rates of Chlamydial infections (based
on DFA test results) amongst various disease groups.
However, statistically signiﬁcant decline was noted only in
the infertility group which showed an overall signiﬁcant
decline in the disease prevalence (Figure 1 and Table 1; χ2
trend=22.97,P = 0.0001).Asimilartrendwasalsoobserved
when the data were compared between the block years I and
II and the block years I and III, for the infertility group only
(Table 1).
In tissue culture isolation, bright apple green ﬂuorescent
para nuclear Chlamydial inclusions were visible in positive
specimens. From the 1507 specimens processed for tissue
culture isolation, 198 (13.1%) gave positive results; from the
same 1507 specimens Chlamydia antigen could be detected
from 275 (18.2%) specimens. The detailed comparative
results between DFA and tissue culture isolation are shown
in Table 2.
In the PCR assay for ampliﬁcation of C. trachomatis
517bp cryptic plasmid gene, 44 out of 333 (13.2%) of
the cervical specimens showed positive results; the same 444 Infectious Diseases in Obstetrics and Gynecology
Table 2: Comparison of DFA with tissue culture isolation.
Tissue culture
DFA Positive (%) Negative (%) Total
Positive 108 167 275 (18.24%)
Negative 90 1142 1232
Total 198 (13.13%) 1309 1507
Characteristics of DFA in relation to tissue culture.
Sensitivity = 54.5% (47.3, 61.6), PPV = 39.2% (33.4, 45.3).
Speciﬁcity = 87.2% (85.3, 89.0), NPV = 92.7% (91.1, 94.0).
Agreement = 82.9% (80.0, 84.8).
PPV: positive predictive value, NPV: negative predictive value, DFA: direct
immunoﬂuorescence assay.
Lane M: 100bp DNA ladder
1234 M 5678
Lanes 1–4: RFLP analysis from conjunctival (eye) specimens
Lanes 5–8: RFLP analysis of endocervical specimens
Figure 2: RFLP analysis of the PCR ampliﬁed MOMP gene from
clinical specimens in 3% agarose gel.
specimens were positive for antigen detection by DFA test:
both the tests showing complete concordant results in these
333 specimens.
From the 50 endocervical specimens processed for the
PCR assay for ampliﬁcation of the MOMP gene, 22 (44%)
were positive. In RFLP pattern analysis, upon examination
of the DNA bands in 3% agarose gel stained with ethidium
bromide, all the cervical specimens showed a similar pat-
tern, which corresponded to published RFLP pattern of C.
trachomatis serovar E. For cervical specimens, after complete
digestion with Alu1 enzyme, 5 DNA bands were visualized,
corresponding to 2 bands each of 100bp, one band of 138bp
and 2 bands each of 250bp. (Figure 2).There was a clear-cut
distinction between the RFLP patterns of conjunctival and
endocervical specimens. The RFLP pattern produced by the
conjunctivalspecimensmatchedwiththoseofC.trachomatis
serovar A [15].
4. Discussion
In the present study, Chlamydia antigen could be detected
in 391 out of 2466 (15.85%) of patients studied over a
16-year period, signiﬁcantly in 27.27% cases with PID and
16.03% cases with cervicitis. (Table 1). Barring a few isolated
reports, no such long-term study regarding involvement
of C. trachomatis in various female genital infections is
available from India. According to the isolated reports,
Chlamydia antigen could be detected in 38.46% of PID
patients from Bombay in 1990 [16], in 35.22% of PID
patients from Delhi in 1991 [17], in 35.22% patients of PID,
and in 42.8% patients of cervicitis from Delhi in 1993 [8].
Results of a few community-based studies spanning 1-2-year
period to determine Chlamydia prevalence in female genital
infectionswereavailable.Accordingtothesereports, in2000,
Chlamydia prevalence was 23.2% in female sex workers
attending STD clinics in Bombay [18], Chlamydia antigen
positivity was 12.2% in women with vaginal discharge
(cervicitis) and 28.7% in all symptomatic women in urban
slums in Delhi in 2000 and 2001, respectively [19, 20]. Since
the current study is based on presence of laboratory proven
Chlamydial infection among broadly symptomatic women
attending hospital during past 16 years, the results are more
or less comparable to other reports from diﬀerent parts of
India. Though we presume that studies reporting higher
positivity rates might have been conducted on very select
group of patients. As was mentioned earlier, in the present
study there was a trend towards an apparent decline in the
antigen positivity rates over the years, the exact reasons for
which are not clear.
Diﬀerentiation of C. trachomatis servoars by the use
of RFLP pattern analysis of ampliﬁed MOMP DNA has
been used widely [9, 10, 21, 22]. Such diﬀerentiation helps
understanding the pathogenesis and epidemiology of the
disease. This method has an advantage, as it alone can
be used for direct typing of most of the serotypes of C.
trachomatis [15, 21]. In a study by Sayada et al. [15], 78%
of the clinical isolates could be typed directly by using Alu
1 enzyme alone. In this study we compared the banding
pattern of Alu1 digested MOMP gene from the clinical
samples with the published pattern in the literature [15]a n d
the analysis showed the presence of C. trachoamtis Es e r o v a r
in the endocervical specimens.Poole and Lamont [23]h a d
concluded from a study that serovars E, D, and F were the
most commonly found serovars in patients with urogenital
infections. We could detect only one genotype, serovar E of
C. trachomatis in the 22 specimens positive in PCR assay
for MOMP gene. Although detection of only one serovar is
uncommon, the small number of specimens processed only
from cervicitis might have been the reason. Nonetheless, it
reveals the most prevalent serovar causing cervicitis.
Although PCR-RFLP is of importance in the epidemi-
ological studies and very little ampliﬁed DNA is required,
it does not reveal the full extent of sequence variation in
some strains [15, 23]. However, the RFLP analysis using the
enzymeAlu1isstillpreferredbymanyanditcandiﬀerentiate
between most of the serovars of C. trachomatis and thus
this could be a starting point for further diﬀerentiationInfectious Diseases in Obstetrics and Gynecology 5
of the isolates by sequencing techniques [24]. Neverthe-
less, RFLP performed directly with cervical specimens in
the present study, showed that, under optimized reaction
conditions, ampliﬁcation of an approximately 1kb omp1
fragment followed by digestion with Alu1 enzyme could
determine the most prevalent serovar of C. trachomatis.
This is in agreement with the observations by others
[21]. For comparison purposes, we had included a few
specimensfromC.trachomatiseyeinfectionsforgenotyping,
these belonged to serovar A which corroborated with our
previous serotyping result [25]. This further strengthens the
authenticity of the results of the present study. Although
we could detect only C. trachomatis serovar E, from India,
others have reported presence of servaors D, E, G I, and F,
representing 92% of their isolates [8]. In another study from
ad i ﬀerent part of world, C. trachomatis serovars D, E, and F
were found to be the most common types by RFLP pattern
analysis in 35 specimens from urogenital infections [26].
5. Conclusion
Overall Chlamydia antigen detection rate varied from 12.2%
to 27% in diﬀerent female genital infection patients (2466)
attending hospital over a period of 16 years in New Delhi,
India. Even though the exact reason was not clear, there was
signiﬁcant decline and an apparent decline in Chlamydia
antigen positivity between years 1994–2000 and 2000–
10, respectively. In the 333 specimens processed for both
antigen detection and PCR assay, equal number of positives
(13.2%) was detected with concordant results. PCR-based
RFLP pattern analysis concluded the prevalent serovar as C.
trachomatis serovar E in cervicitis patients.
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